Tularemia Vaccine Development Contract: Monthly Technical Report
Period: 2/1/2010 to 2/28/2010
Due Date: 3/15/2010 and Prepared by: C. Rick Lyons, Barbara Griffith, Terry Wu, Bob
Sherwood, Julie Wilder, Julie Hutt, Michelle Valderas, Trevor Brasel, Dana Pohlman, Mitch
Magee, Kathryn Sykes, Stephen Johnston, Karl Klose, Bernard Arulanandam, Justin Skoble
Contract No.
ADB Contract No.
HHSN266200500040-C
N01-AI-50040
Contract Title:
Tularemia Vaccine Development Team
Performance Period: 2/1 to 2/28/2010
Contractor Name:
University of New Mexico Health Science Center
Contractor Address: Controller’s Office MSC-09-5220
1 University of New Mexico
Albuquerque, New Mexico 87131-0001
Authors:
C. Rick Lyons, MD, PhD and Barbara B. Griffith, MS
Date of submission: 3/12/2010
Monthly
Technical Report:
Based on Contributions from ASU, Cerus/Aduro,
LBERI, UNM and UTSA
Page 1 of 6
Tularemia Vaccine Development Contract: Monthly Technical Report
Period: 2/1/2010 to 2/28/2010
Due Date: 3/15/2010 and Prepared by: C. Rick Lyons, Barbara Griffith, Terry Wu, Bob
Sherwood, Julie Wilder, Julie Hutt, Michelle Valderas, Trevor Brasel, Dana Pohlman, Mitch
Magee, Kathryn Sykes, Stephen Johnston, Karl Klose, Bernard Arulanandam, Justin Skoble
Contract No. HHSN266200500040-C
ADB Contract No. N01-AI-50040
Section I: Purpose and Scope of Effort
The Tularemia Vaccine Development Contract will lead to vaccine candidates, two animal
models and cellular assays vital for testing vaccine efficacy.
Sections II and III: Progress and Planning Presented by Institution
1. Active milestones: 2, 8, 9, 10(UNM/LBERI),11(UNM/LBERI), merged
12/13/14/15(UNM/LBERI), merged 17/18/19/20/21/22(UNM/LBERI), reopened
28, 29 (UNM/LBERI), 52, 53, 54, 55, 56, 57
2. Completed milestones: 1, 3, 4, 5, 6, 7, 16, 25, 26, 27, 32, 33, 34 (UNM/ASU), 35
(ASU/UNM), 36, 39, 40, 43 (UTSA), 48,49, 50, 51
3. Inactive milestones: 23, 24, 30, merged 37/38 (ASU J/ LBERI/ ASU S), 59
4. Milestones terminated after initiation: 41, 42, 44, 46, (MSCR will be written)
5. Milestones terminated before initiated: 43 (Cerus), 45, 47, 58, (MSCR will not be
written)
See the attached 5 Powerpoint presentations annotated with minutes
1.
2.
3.
4.
5.
UTSA Monthly Technical Call 2/16/2010
ASU Monthly Technical Call 2/23/2010
LBERI Monthly Technical Call 3/2/2010
UNM Monthly Technical Call 3/3/2010
Cerus Monthly Technical Call 3/9/2010
Page 2 of 6
Tularemia Vaccine Development Contract: Monthly Technical Report
Period: 2/1/2010 to 2/28/2010
Due Date: 3/15/2010 and Prepared by: C. Rick Lyons, Barbara Griffith, Terry Wu, Bob
Sherwood, Julie Wilder, Julie Hutt, Michelle Valderas, Trevor Brasel, Dana Pohlman, Mitch
Magee, Kathryn Sykes, Stephen Johnston, Karl Klose, Bernard Arulanandam, Justin Skoble
ACRONYMS FOR TECHNICAL REPORTS



































ABSL3: Animal Biosafety Level 3 lab
AM: alveolar macrophages
ASU: Arizona State University
BLD: below limit of detection
BMDM: bone marrow derived macrophages
BP: base pair
BSL2: Biosafety Level 2 lab
BSL3: Biosafety Level 3 lab
CD14: cell marker for monocytes in humans and non-human primates
CD16: cell marker for Natural killer cells in humans and non-human primates
CD 56: cell marker for Natural killer cells in humans but may only be expressed in monocytes in
non-human primates
C: centrigrade
cDNA: complimentary deoxyribonucleic acid
CDA: confidentiality and disclosure agreement
CDM: Chamberlains defined media
CFSE: fluorescent dye called carboxyfluorescein succinimidyl ester
CFU: colony forming units
COA: contract officers authorization
CRDA: Cooperative research and development agreement
C-term: Carboxy terminus
DNA: deoxyribonucleic acid
DO: dissolved oxygen
DVC: Dynport Vaccine Company
ED50: Effective Dose, 50 % dead
ELISA: enzyme-linked immunosorbent assay
ELISpot: enzyme-linked immunospot assay
EOH: Employee Occupational Health
FACS: Fluorescence-activated cell sorting
FDA: Federal Drug Administration
FF: formalin fixed
FSC: forward scatter, equivalent to cell size FT or Ft or F. tularensis: Francisella tularensis
GDP: genome directed primers
GI: gastrointestinal
GLP: good laboratory practice
KBMA: killed but metabolically active
Page 3 of 6
Tularemia Vaccine Development Contract: Monthly Technical Report
Period: 2/1/2010 to 2/28/2010
Due Date: 3/15/2010 and Prepared by: C. Rick Lyons, Barbara Griffith, Terry Wu, Bob
Sherwood, Julie Wilder, Julie Hutt, Michelle Valderas, Trevor Brasel, Dana Pohlman, Mitch
Magee, Kathryn Sykes, Stephen Johnston, Karl Klose, Bernard Arulanandam, Justin Skoble





































HK: heat killed
HTP: high through put
IAA: interagency agreement
IACUC: Institutional animal care and use committee
ICS: Intracellular staining
ID: intradermal
IFNγ: interferon gamma
IgG: immunoglobulin, G class
IgA: immunoglobulin, A class
IgM: immunoglobulin, M class
IL2: interleukin 2
IM: intramuscular
IN: intranasal
IND: investigational new drug
IP: intraperitoneal
IRB: institutional review board
IRS: immune rat sera
IT: intratracheal
IV: intravenous
IVT: in vitro translation/transcription
KB: kilobase
L: liter
LAPT: Linear Amplification of Procaryotic Transpcript
LBERI: Lovelace Biomedical and Environmental Research Institute
LD50: Lethal dose 50% dead
LD99: lethal dose, 99% dead
Lm: Listeria monocytogenes
LN: lymph node
LPS: lipopolysaccharide
LRRI: Lovelace Respiratory Research Institute
LVS: Live vaccine strain (tularemia)
NHP: nonhuman primate
MAb: monoclonal antibody
MDM: monocyte derived macrophages
mL: milliliter
MLN: mesenteric lymph node
mM: Milli molar
Page 4 of 6
Tularemia Vaccine Development Contract: Monthly Technical Report
Period: 2/1/2010 to 2/28/2010
Due Date: 3/15/2010 and Prepared by: C. Rick Lyons, Barbara Griffith, Terry Wu, Bob
Sherwood, Julie Wilder, Julie Hutt, Michelle Valderas, Trevor Brasel, Dana Pohlman, Mitch
Magee, Kathryn Sykes, Stephen Johnston, Karl Klose, Bernard Arulanandam, Justin Skoble





































MOI: multiplicity of infection
MS: Milestone
MSCR: Milestone Completion Report
MTA: material transfer agreement
MTS reagent: (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt
N: number
NIAID: National Institute of Allergy and Infectious Disease
NRS: normal rat sera
N-term: amino- terminus
OD: optical density
OMP:outer membrane proteins
ORF: open reading frame
P60: constitutively expressed protein
PBMC: peripheral blood mononuclear cells
PBS: phosphate buffered saline
PFA: paraformaldehyde
pM: pico Molar
pmol: picomole
PCR: polymerase chain reaction
QA: quality assurance
QC: quality control
qPCR: quantitative polymerase chain reaction
RNA: ribonucleic acid
RNU: T-cell deficient nude rats
SC: subcutaneous
SDS: sodium dodecyl sulfate
SCHU S4: virulent strain of Francisella tularensis
SIP: Special Immunizations Program at USAMRIID
SOP: standard operating procedure
SSC: side scatter, equivalent to cell density or granularity
TBLN: tracheobronchial lymph node
TFF:tangential flow filtration
Tn: transposon
TNFα: tumor necrosis factor alpha
TVDC: Tularemia vaccine development contract
uL: microliter
UNM: University of New Mexico
Page 5 of 6
Tularemia Vaccine Development Contract: Monthly Technical Report
Period: 2/1/2010 to 2/28/2010
Due Date: 3/15/2010 and Prepared by: C. Rick Lyons, Barbara Griffith, Terry Wu, Bob
Sherwood, Julie Wilder, Julie Hutt, Michelle Valderas, Trevor Brasel, Dana Pohlman, Mitch
Magee, Kathryn Sykes, Stephen Johnston, Karl Klose, Bernard Arulanandam, Justin Skoble






USAMMDA: United States Army Medical Materiel Development Activity
USAMRIID: United States Army Medical Research Institute for Infectious Disease
UTSA: University of Texas at San Antonio
Vvm: volume of air per culture volume per minute
WFI: water for injection
WT: wild type
Page 6 of 6